245 related articles for article (PubMed ID: 17017977)
21. Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
Su X; Pradaux-Caggiano F; Vicker N; Thomas MP; Halem H; Culler MD; Potter BV
ChemMedChem; 2011 Sep; 6(9):1616-29. PubMed ID: 21714097
[TBL] [Abstract][Full Text] [Related]
22. 11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?
Seckl JR
Front Neuroendocrinol; 1997 Jan; 18(1):49-99. PubMed ID: 9000459
[TBL] [Abstract][Full Text] [Related]
23. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Hughes KA; Webster SP; Walker BR
Expert Opin Investig Drugs; 2008 Apr; 17(4):481-96. PubMed ID: 18363514
[TBL] [Abstract][Full Text] [Related]
24. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
25. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
26. 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.
Gathercole LL; Lavery GG; Morgan SA; Cooper MS; Sinclair AJ; Tomlinson JW; Stewart PM
Endocr Rev; 2013 Aug; 34(4):525-55. PubMed ID: 23612224
[TBL] [Abstract][Full Text] [Related]
27. Progress in 11β-HSD1 inhibitors for the treatment of metabolic diseases: A comprehensive guide to their chemical structure diversity in drug development.
Chuanxin Z; Shengzheng W; Lei D; Duoli X; Jin L; Fuzeng R; Aiping L; Ge Z
Eur J Med Chem; 2020 Apr; 191():112134. PubMed ID: 32088493
[TBL] [Abstract][Full Text] [Related]
28. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
Rauz S; Cheung CM; Wood PJ; Coca-Prados M; Walker EA; Murray PI; Stewart PM
QJM; 2003 Jul; 96(7):481-90. PubMed ID: 12881590
[TBL] [Abstract][Full Text] [Related]
30. Effects of cortisol and oestradiol on hepatic 11beta-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor proteins in late-gestation sheep fetus.
Gupta S; Alfaidy N; Holloway AC; Whittle WL; Lye SJ; Gibb W; Challis JR
J Endocrinol; 2003 Feb; 176(2):175-84. PubMed ID: 12553866
[TBL] [Abstract][Full Text] [Related]
31. 11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.
Chapman K; Holmes M; Seckl J
Physiol Rev; 2013 Jul; 93(3):1139-206. PubMed ID: 23899562
[TBL] [Abstract][Full Text] [Related]
32. Targeting 11β-hydroxysteroid dehydrogenases: a novel approach to manipulating local glucocorticoid levels with implications for rheumatic disease.
Hardy RS; Seibel MJ; Cooper MS
Curr Opin Pharmacol; 2013 Jun; 13(3):440-4. PubMed ID: 23540586
[TBL] [Abstract][Full Text] [Related]
33. Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action.
Seckl JR; Walker BR
Endocrinology; 2001 Apr; 142(4):1371-6. PubMed ID: 11250914
[TBL] [Abstract][Full Text] [Related]
34. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z
Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704
[TBL] [Abstract][Full Text] [Related]
35. Green tea and one of its constituents, Epigallocatechine-3-gallate, are potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
Hintzpeter J; Stapelfeld C; Loerz C; Martin HJ; Maser E
PLoS One; 2014; 9(1):e84468. PubMed ID: 24404164
[TBL] [Abstract][Full Text] [Related]
36. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
Tomlinson JW; Walker EA; Bujalska IJ; Draper N; Lavery GG; Cooper MS; Hewison M; Stewart PM
Endocr Rev; 2004 Oct; 25(5):831-66. PubMed ID: 15466942
[TBL] [Abstract][Full Text] [Related]
37. In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid.
Diederich S; Quinkler M; Mai K; Schöneshöfer M; Baehr V; Pfeiffer A; Oelkers W; Eigendorff E
Horm Metab Res; 2011 Jan; 43(1):66-71. PubMed ID: 20925019
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in the discovery of 11beta-HSD1 inhibitors.
Boyle CD
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
[TBL] [Abstract][Full Text] [Related]
39. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
40. Application of ELISA Technique and Human Microsomes in the Search for 11
Kupczyk D; Studzińska R; Bilski R; Woźniak A
Biomed Res Int; 2019; 2019():5747436. PubMed ID: 31214617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
